Tatva Chintan Pharma Intrinsic Value
TATVA • Chemicals
Current Stock Price
₹1202.30
Primary Intrinsic Value
₹360.69
Market Cap
₹2765 Cr
-70.0%
Downside
Median Value
₹360.69
Value Range
₹321 - ₹601
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
TATVA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹360.69 | ₹288.55 - ₹432.83 | -70.0% | EPS: ₹16.96, Sector P/E: 12x |
| Book Value Method | asset | ₹321.30 | ₹289.17 - ₹353.43 | -73.3% | Book Value/Share: ₹321.30, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹360.69 | ₹324.62 - ₹396.76 | -70.0% | Revenue/Share: ₹217.39, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹480.92 | ₹432.83 - ₹529.01 | -60.0% | EBITDA: ₹92.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹480.92 | ₹384.74 - ₹577.10 | -60.0% | CF Growth: 5.7%, Discount: 15% |
| PEG Ratio Method | growth | ₹360.69 | ₹324.62 - ₹396.76 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹360.69 | ₹324.62 - ₹396.76 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹601.15 | ₹541.03 - ₹661.26 | -50.0% | ROE: 5.4%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹360.69 | ₹324.62 - ₹396.76 | -70.0% | EPS: ₹16.96, BVPS: ₹321.30 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
TATVA Intrinsic Value Analysis
What is the intrinsic value of TATVA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Tatva Chintan Pharma (TATVA) is ₹360.69 (median value). With the current market price of ₹1202.30, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹321.30 to ₹601.15, indicating ₹321.30 - ₹601.15.
Is TATVA undervalued or overvalued?
Based on our multi-method analysis, Tatva Chintan Pharma (TATVA) appears to be trading above calculated value by approximately 70.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 265.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.4% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.60x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Tatva Chintan Pharma
Additional stock information and data for TATVA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹25 Cr | ₹-8 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹98 Cr | ₹38 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹28 Cr | ₹-23 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹20 Cr | ₹-79 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹20 Cr | ₹10 Cr | Positive Free Cash Flow | 7/10 |